TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Phase III, Double-Blind, Placebo-Controlled Trial of Memantine for Prevention of Cognitive Dysfunction in Patients Receiving Whole-Brain Radiotherapy
Brief Summary: RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy.

PURPOSE: This randomized phase III trial is studying memantine to see how well it works compared to a placebo in preventing side effects caused by whole-brain radiation therapy in patients with brain metastases from solid tumors.


Options:
A: Arm Label: WBRT with Hippocampal Avoidance; Type: OTHER; Interventions: Radiation: intensity-modulated radiation therapy | Intervention Type: RADIATION; Name: intensity-modulated radiation therapy; Assigned to Arm(s): WBRT with Hippocampal Avoidance
B: Arm Label: WBRT+Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine, Radiation: Whole brain radiation therapy | Arm Label: WBRT+Placebo; Type: ACTIVE_COMPARATOR; Interventions: Other: Placebo, Radiation: Whole brain radiation therapy | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): WBRT+Memantine | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): WBRT+Placebo | Intervention Type: RADIATION; Name: Whole brain radiation therapy; Assigned to Arm(s): WBRT+Memantine, WBRT+Placebo
C: Arm Label: WBRT + Memantine; Type: EXPERIMENTAL; Interventions: Drug: Memantine, Radiation: Whole brain radiation therapy | Arm Label: HA-WBRT/IMRT+ Memantine; Type: EXPERIMENTAL; Interventions: Radiation: Whole brain radiation therapy with hippocampal avoidance, Drug: Memantine | Intervention Type: RADIATION; Name: Whole brain radiation therapy with hippocampal avoidance; Assigned to Arm(s): HA-WBRT/IMRT+ Memantine | Intervention Type: DRUG; Name: Memantine; Assigned to Arm(s): HA-WBRT/IMRT+ Memantine, WBRT + Memantine | Intervention Type: RADIATION; Name: Whole brain radiation therapy; Assigned to Arm(s): WBRT + Memantine
D: Arm Label: ketogenic diet and transient fasting; Type: EXPERIMENTAL; Interventions: Dietary Supplement: calorie-restricted ketogenic diet and transient fasting | Arm Label: standard nutrition; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: standard nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: calorie-restricted ketogenic diet and transient fasting; Assigned to Arm(s): ketogenic diet and transient fasting | Intervention Type: DIETARY_SUPPLEMENT; Name: standard nutrition; Assigned to Arm(s): standard nutrition

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventive Care of Chronic Cervical Pain and Disabilities; Comparison of Spinal Manipulative Therapy and Individualized Home Exercise Programs
Brief Summary: The aim of this study is to determine which of tertiary prevention spinal manipulative therapy (SMT) or a home exercise program is the more efficient approach to reduce pain and increase functional capacity, quality of life and general health condition. To do so, 60 participants with chronic cervical pain, will be recruited and divided into 3 groups according to the intervention they will receive: control group, experimental group 1 who will receive preventive chiropractic care in the form of spinal manipulations and experimental group 2 will have to perform an individualized home exercise program on a daily basis. We hypothesize that a group of patient receiving SMT + a home exercise program will present less pain and functional disabilities over a 1 year period. The innovative value of this project is mainly related to the fact that it will generate new and potentially very useful data concerning the clinical significance of preventive chiropractic care. Moreover, such data will be beneficial to our profession as chiropractic makes a step towards prevention, wellness and public health.


Options:
A: Arm Label: wait and see; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: collar; Type: EXPERIMENTAL; Interventions: Other: cervical collar | Arm Label: physiotherapy; Type: EXPERIMENTAL; Interventions: Other: physiotherapy | Intervention Type: OTHER; Name: cervical collar; Assigned to Arm(s): collar | Intervention Type: OTHER; Name: physiotherapy; Assigned to Arm(s): physiotherapy
B: Arm Label: Specific resistance training; Type: ACTIVE_COMPARATOR; Interventions: Other: Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck; Assigned to Arm(s): Specific resistance training
C: Intervention Type: PROCEDURE; Name: Chiropractic spinal manipulation; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Acetaminophen; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Self-care; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Non-Steroidal anti-inflammatory drugs (NSAIDS); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Tylenol with codeine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: spinal manipulation | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Other: Spinal manipulation + exercises | Intervention Type: OTHER; Name: spinal manipulation; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Spinal manipulation + exercises; Assigned to Arm(s): 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Open-label, Three-arm, Active-controlled Study to Assess the Efficacy and Safety of the Oral Contraceptive SH T00186D (0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone) in Two Flexible Extended Regimens and a Conventional Regimen of YAZ in 1756 Healthy Females for 1 Year
Brief Summary: The purpose of this study is to determine whether the study drug is safe and effective.


Options:
A: Intervention Type: BEHAVIORAL; Name: Quick start oral contraceptive initiation; Assigned to Arm(s): N/A
B: Arm Label: 1 Standard Care (SC); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2 Standard Care + Educational (SCE); Type: OTHER; Interventions: Behavioral: educational instruction in clinic | Arm Label: 3 Standard Care + Educational + Phone Calls (SCEP); Type: OTHER; Interventions: Behavioral: educational instruction and phone follow-up | Intervention Type: BEHAVIORAL; Name: educational instruction and phone follow-up; Assigned to Arm(s): 3 Standard Care + Educational + Phone Calls (SCEP) | Intervention Type: BEHAVIORAL; Name: educational instruction in clinic; Assigned to Arm(s): 2 Standard Care + Educational (SCE)
C: Arm Label: NOMAC-E2; Type: EXPERIMENTAL; Interventions: Drug: NOMAC-E2 | Arm Label: DRSP-EE; Type: ACTIVE_COMPARATOR; Interventions: Drug: DRSP-EE | Intervention Type: DRUG; Name: NOMAC-E2; Assigned to Arm(s): NOMAC-E2 | Intervention Type: DRUG; Name: DRSP-EE; Assigned to Arm(s): DRSP-EE
D: Arm Label: Flexible (extended) regimen no. 1 of EE20/DRSP (BAY86-5300); Type: EXPERIMENTAL; Interventions: Drug: EE20/DRSP (BAY86-5300) | Arm Label: Flexible (extended) regimen no. 2 of EE20/DRSP (BAY86-5300); Type: EXPERIMENTAL; Interventions: Drug: EE20/DRSP (BAY86-5300) | Arm Label: Conventional regimen of EE20/DRSP (YAZ, BAY86-5300); Type: ACTIVE_COMPARATOR; Interventions: Drug: EE20/DRSP (YAZ, BAY86-5300) | Intervention Type: DRUG; Name: EE20/DRSP (BAY86-5300); Assigned to Arm(s): Flexible (extended) regimen no. 1 of EE20/DRSP (BAY86-5300) | Intervention Type: DRUG; Name: EE20/DRSP (BAY86-5300); Assigned to Arm(s): Flexible (extended) regimen no. 2 of EE20/DRSP (BAY86-5300) | Intervention Type: DRUG; Name: EE20/DRSP (YAZ, BAY86-5300); Assigned to Arm(s): Conventional regimen of EE20/DRSP (YAZ, BAY86-5300)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improving Medication Adherence for Osteoporosis: A Community-Based Randomized Controlled Trial
Brief Summary: Osteoporosis is a common bone disease in older adults in which the bones become weaker and prone to fracture. Medications are available to slow or even stop disease progression. However, very few adults who are prescribed osteoporosis medications actually follow through with filling their prescriptions and taking the medications. Ways to improve medication use have not been well developed or adequately tested. The purpose of this study is to evaluate a telephone coaching program, with or without helpful adherence notifications to doctors, in improving treatment adherence in older adults who are starting an osteoporosis medication.


Options:
A: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Re-Mission; Assigned to Arm(s): N/A
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mailed education | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone coaching program for patients | Arm Label: C; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone coaching program for patients, Behavioral: Medication adherence alert program for doctors | Intervention Type: BEHAVIORAL; Name: Mailed education; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Telephone coaching program for patients; Assigned to Arm(s): B, C | Intervention Type: BEHAVIORAL; Name: Medication adherence alert program for doctors; Assigned to Arm(s): C
D: Intervention Type: BEHAVIORAL; Name: food; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Feasibility of a Polypill Clinical Trial for Primary Prevention of Cardiovascular Disease: A Pilot Study
Brief Summary: The purpose of this pilot study is to provide data on the feasibility of conducting a large clinical trial on the polypill (combination of aspirin, angiotensin converting enzyme inhibitor, thiazide diuretic, and statin) for primary prevention of cardiovascular disease (CVD). We hypothesized that A "polypill" comprising the aforementioned four components would significantly reduce the estimated 10-year total CVD risk score with high adherence and no significant increase in adverse effects compared to the standard practice.


Options:
A: Arm Label: Free combination; Type: ACTIVE_COMPARATOR; Interventions: Drug: perindopril, indapamide , amlodipine | Arm Label: Tripliam; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tripliam (perindopril, indapamide, amlodipine) | Intervention Type: DRUG; Name: perindopril, indapamide , amlodipine; Assigned to Arm(s): Free combination | Intervention Type: DRUG; Name: Tripliam (perindopril, indapamide, amlodipine); Assigned to Arm(s): Tripliam
B: Arm Label: The Red Heart Pill 2b (Polypill) (A); Type: EXPERIMENTAL; Interventions: Drug: Red Heart Pill 2b (Polypill) | Arm Label: Standard Practice Group (B); Type: ACTIVE_COMPARATOR; Interventions: Other: Standard Practice | Intervention Type: DRUG; Name: Red Heart Pill 2b (Polypill); Assigned to Arm(s): The Red Heart Pill 2b (Polypill) (A) | Intervention Type: OTHER; Name: Standard Practice; Assigned to Arm(s): Standard Practice Group (B)
C: Arm Label: Test and reference formulations; Type: EXPERIMENTAL; Interventions: Drug: Test formulation, Drug: Reference formulation | Intervention Type: DRUG; Name: Test formulation; Assigned to Arm(s): Test and reference formulations | Intervention Type: DRUG; Name: Reference formulation; Assigned to Arm(s): Test and reference formulations
D: Arm Label: Caduet; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine besylate/atorvastatin calcium single pill combination | Intervention Type: DRUG; Name: Amlodipine besylate/atorvastatin calcium single pill combination; Assigned to Arm(s): Caduet

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Varenicline in Methadone-Stabilized Cocaine Users
Brief Summary: Cocaine addiction continues to be an important public health problem in the US with a significant cost to the individual and society. Among substance abusers, cocaine use has been recognized as a significant problem especially in methadone-maintenance patients. In several studies, rates of cocaine use have been reported to range from 30 to over 60 percent of those in methadone maintenance programs (Condelli et al. 1991; Hunt et al. 1984; Kidorf and Stitzer 1993; Kosten et al. 1988). In these patients, cocaine use seems to be a predictor of poor clinical outcome (Hartel et al. 1995; Kosten et al. 1987a). The development of effective pharmacotherapies for cocaine use disorders, especially in the opioid-dependent population is of great importance. Unfortunately, such effective pharmacotherapies do not exist.

1. To determine the safety and tolerability of varenicline in cocaine-using methadone-stabilized subjects.
2. To determine if varenicline is efficacious in reducing cocaine-use in methadone-stabilized subjects.


Options:
A: Arm Label: CoSTED Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: CoSTED Intervention | Arm Label: Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CoSTED Intervention; Assigned to Arm(s): CoSTED Intervention
B: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo
D: Arm Label: NicVAX conjugate vaccine; Type: EXPERIMENTAL; Interventions: Biological: NicVAX vaccine, Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Varenicline | Intervention Type: BIOLOGICAL; Name: NicVAX vaccine; Assigned to Arm(s): NicVAX conjugate vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): NicVAX conjugate vaccine, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Varenicline in Methadone-Stabilized Cocaine Users
Brief Summary: Cocaine addiction continues to be an important public health problem in the US with a significant cost to the individual and society. Among substance abusers, cocaine use has been recognized as a significant problem especially in methadone-maintenance patients. In several studies, rates of cocaine use have been reported to range from 30 to over 60 percent of those in methadone maintenance programs (Condelli et al. 1991; Hunt et al. 1984; Kidorf and Stitzer 1993; Kosten et al. 1988). In these patients, cocaine use seems to be a predictor of poor clinical outcome (Hartel et al. 1995; Kosten et al. 1987a). The development of effective pharmacotherapies for cocaine use disorders, especially in the opioid-dependent population is of great importance. Unfortunately, such effective pharmacotherapies do not exist.

1. To determine the safety and tolerability of varenicline in cocaine-using methadone-stabilized subjects.
2. To determine if varenicline is efficacious in reducing cocaine-use in methadone-stabilized subjects.


Options:
A: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Bupropion/Low Contact; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Placebo/Low Contact; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Bupropion/High Contact; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion and NRT | Arm Label: Extended Placebo/High Contact; Type: PLACEBO_COMPARATOR; Interventions: Drug: Bupropion and NRT | Intervention Type: DRUG; Name: Bupropion and NRT; Assigned to Arm(s): Brief Treatment, Extended Bupropion/High Contact, Extended Bupropion/Low Contact, Extended Placebo/High Contact, Extended Placebo/Low Contact
B: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Pharmacotherapies for Smoking Cessation | Intervention Type: DRUG; Name: Pharmacotherapies for Smoking Cessation; Assigned to Arm(s): 1, 2
D: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Varenicline in Methadone-Stabilized Cocaine Users
Brief Summary: Cocaine addiction continues to be an important public health problem in the US with a significant cost to the individual and society. Among substance abusers, cocaine use has been recognized as a significant problem especially in methadone-maintenance patients. In several studies, rates of cocaine use have been reported to range from 30 to over 60 percent of those in methadone maintenance programs (Condelli et al. 1991; Hunt et al. 1984; Kidorf and Stitzer 1993; Kosten et al. 1988). In these patients, cocaine use seems to be a predictor of poor clinical outcome (Hartel et al. 1995; Kosten et al. 1987a). The development of effective pharmacotherapies for cocaine use disorders, especially in the opioid-dependent population is of great importance. Unfortunately, such effective pharmacotherapies do not exist.

1. To determine the safety and tolerability of varenicline in cocaine-using methadone-stabilized subjects.
2. To determine if varenicline is efficacious in reducing cocaine-use in methadone-stabilized subjects.


Options:
A: Intervention Type: DRUG; Name: varenicline (CP-526,555); Assigned to Arm(s): N/A
B: Arm Label: E-cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Traditional cigarettes only; Type: N/A; Interventions: N/A | Arm Label: Mixed group; Type: N/A; Interventions: N/A
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo
D: Intervention Type: DRUG; Name: dianicline; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Varenicline in Methadone-Stabilized Cocaine Users
Brief Summary: Cocaine addiction continues to be an important public health problem in the US with a significant cost to the individual and society. Among substance abusers, cocaine use has been recognized as a significant problem especially in methadone-maintenance patients. In several studies, rates of cocaine use have been reported to range from 30 to over 60 percent of those in methadone maintenance programs (Condelli et al. 1991; Hunt et al. 1984; Kidorf and Stitzer 1993; Kosten et al. 1988). In these patients, cocaine use seems to be a predictor of poor clinical outcome (Hartel et al. 1995; Kosten et al. 1987a). The development of effective pharmacotherapies for cocaine use disorders, especially in the opioid-dependent population is of great importance. Unfortunately, such effective pharmacotherapies do not exist.

1. To determine the safety and tolerability of varenicline in cocaine-using methadone-stabilized subjects.
2. To determine if varenicline is efficacious in reducing cocaine-use in methadone-stabilized subjects.


Options:
A: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Sugar Pill or Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sugar pill or Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Sugar pill or Placebo; Assigned to Arm(s): Sugar Pill or Placebo
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablet is made of lactose | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo tablet is made of lactose; Assigned to Arm(s): control group
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline Tartarate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline Tartarate; Assigned to Arm(s): varenicline
D: Intervention Type: DRUG; Name: zyban; Assigned to Arm(s): N/A

Answer: A